These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25071019)

  • 1. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.
    Xiong X; Arvizo RR; Saha S; Robertson DJ; McMeekin S; Bhattacharya R; Mukherjee P
    Oncotarget; 2014 Aug; 5(15):6453-65. PubMed ID: 25071019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
    Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
    Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells.
    Saydaminova K; Strauss R; Xie M; Bartek J; Richter M; van Rensburg R; Drescher C; Ehrhardt A; Ding S; Lieber A
    Cancer Biol Ther; 2016 Oct; 17(10):1079-1088. PubMed ID: 27574825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
    Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT.
    Kaushik NK; Kaushik N; Yoo KC; Uddin N; Kim JS; Lee SJ; Choi EH
    Biomaterials; 2016 May; 87():118-130. PubMed ID: 26921841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gold nanoparticles enhance cisplatin delivery and potentiate chemotherapy by decompressing colorectal cancer vessels.
    Zhao X; Pan J; Li W; Yang W; Qin L; Pan Y
    Int J Nanomedicine; 2018; 13():6207-6221. PubMed ID: 30349245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
    J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
    Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
    J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzimidazole-Based Organic-Inorganic Gold Nanohybrids Suppress Invasiveness of Cancer Cells by Modulating EMT Signaling Cascade.
    Dhanwal V; Katoch A; Nayak D; Chakraborty S; Gupta R; Kumar A; Gupta PN; Singh N; Kaur N; Goswami A
    ACS Appl Bio Mater; 2021 Jan; 4(1):470-482. PubMed ID: 35014298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.
    Kip B; Tunc CU; Aydin O
    Ultrason Sonochem; 2022 Jan; 82():105903. PubMed ID: 34974392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.